{"id":"dornase-alfa-inhalant-solution-pulmozyme","safety":{"commonSideEffects":[{"rate":"12-13%","effect":"Voice hoarseness"},{"rate":"8-10%","effect":"Pharyngitis"},{"rate":"1-2%","effect":"Laryngitis"},{"rate":"1-2%","effect":"Chest pain"},{"rate":"1-2%","effect":"Hemoptysis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"In cystic fibrosis patients, neutrophil infiltration releases large amounts of DNA into the airways, which increases sputum viscosity and impairs mucociliary clearance. Dornase alfa enzymatically degrades this extracellular DNA, reducing sputum viscoelasticity and facilitating airway drainage. This improves lung function and reduces respiratory infections in CF patients.","oneSentence":"Dornase alfa is a recombinant human deoxyribonuclease that cleaves extracellular DNA in airway secretions, reducing mucus viscosity and improving clearance.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:09:51.086Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cystic fibrosis with FEV1 ≥40% predicted"},{"name":"Reduction of respiratory tract infections in cystic fibrosis patients"}]},"trialDetails":[],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Dornase Alfa Inhalant Solution [Pulmozyme]","genericName":"Dornase Alfa Inhalant Solution [Pulmozyme]","companyName":"University Hospital, Strasbourg, France","companyId":"university-hospital-strasbourg-france","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dornase alfa is a recombinant human deoxyribonuclease that cleaves extracellular DNA in airway secretions, reducing mucus viscosity and improving clearance. Used for Cystic fibrosis with FEV1 ≥40% predicted, Reduction of respiratory tract infections in cystic fibrosis patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}